| Literature DB >> 32959656 |
Guang Huang1, Claribel Murillo Solano2, Joel Melendez2, Justin Shaw2, Jennifer Collins2, Robert Banks3, Arash Keshavarzi Arshadi2, Rachasak Boonhok4,5, Hui Min4, Jun Miao4, Debopam Chakrabarti2, Yu Yuan1.
Abstract
There is an urgent need to develop new efficacious antimalarials to address the emerging drug-resistant clinical cases. Our previous phenotypic screening identified styrylquinoline UCF501 as a promising antimalarial compound. To optimize UCF501, we herein report a detailed structure-activity relationship study of 2-arylvinylquinolines, leading to the discovery of potent, low nanomolar antiplasmodial compounds against a Plasmodium falciparum CQ-resistant Dd2 strain, with excellent selectivity profiles (resistance index < 1 and selectivity index > 200). Several metabolically stable 2-arylvinylquinolines are identified as fast-acting agents that kill asexual blood-stage parasites at the trophozoite phase, and the most promising compound 24 also demonstrates transmission blocking potential. Additionally, the monophosphate salt of 24 exhibits excellent in vivo antimalarial efficacy in the murine model without noticeable toxicity. Thus, the 2-arylvinylquinolines represent a promising class of antimalarial drug leads.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32959656 PMCID: PMC7605213 DOI: 10.1021/acs.jmedchem.0c00858
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446